Sunshine Biopharma, Inc. (SBFM)
SBFMNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.69
-0.0590 (-2.15%) today
Regular session, Nov 12, 1:13 PM ET
- Market cap
- $2.05m
- P/E
- –
- EPS, last 4 quarters
- $-203.00
- Dividend yield
- –
- Day range
- $2.69 to $2.75
- 52-week range
- $2.53 to $464.00
- Average volume
- –
- Previous close
- $2.75
Earnings
Next report
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $9.42m | $8.58m | $8.09m | $9.26m |
| Gross profit | $3.07m | $3.03m | $2.18m | $2.43m |
| Operating income | -$1.09m | -$1.79m | -$1.40m | -$1.61m |
| Net income | -$884.0k | -$2.14m | -$1.24m | -$1.56m |
Last four quarters: revenue $35.35m, margin -16.5%, free cash flow -$5.37m
News
8 latest- Sunshine Biopharma Consensus Price Target Raised 1,900% to $1,142.40Fintel · Nov 1, 2026
- Sunshine Biopharma Prices $6 Million Public Offering; Stock Down RTTNews · Oct 8, 2026
- Sunshine Biopharma Expands Oncology Support Portfolio With Generic Zofran Launch In Canada RTTNews · Sep 24, 2026
- Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should KnowZacks · Sep 24, 2026
- Sunshine Biopharma Launches Generic Ondansetron Tablets In Canada RTTNews · Sep 24, 2026
- Pre-Market Movers: BJDX, PMI, SBFM Drive Momentum RTTNews · Jun 2, 2026
- Sunshine Biopharma Shares Jump 66% Pre-Market After Reverse Split; Canadian OK For Rivaroxaban RTTNews · Jun 2, 2026
- Weekly Buzz: GH Wins FDA Nod; NMPA Green Lights HCM; MDT To Acquire SPR ; BIIB HALTS BIIB112 RTTNews · May 22, 2026
The company
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- sunshinebiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.